US FDA Declines to Approve Aldeyra’s Eye Disorder Drug, Shares Slump

by Medscape • 2026/03/17 • 0 Comments

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...
Reuters Health Information

← Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Credo Launches 800G ZeroFlap Optical Transceivers Engineered for AI Networks →

Post navigation